This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Clinical Trials Remove Recombinant Antibody Related Topics
Antibody Immune Response Clinical Trials Containment Clinical Development Medicine Trials Life Science Protein Genetics More Related Topics >
article thumbnail

Grifols’ Innovation Strategy in the Plasma Medicine Space

XTalks

DECEMBER 12, 2023

Our pipeline, for example, includes a new class of recombinant antibodies. Within the next few months we’re expecting topline results from a Phase III clinical trial on a next-generation fibrinogen, an important plasma protein essential for blood clotting. What are key pipeline initiatives for Grifols in the coming years?

Medicine 111
Medicine Recombinant Antibody Protein Antibody 111
article thumbnail

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

The Pharma Data

JANUARY 18, 2021

IN FRANCE, FOUR CLINICAL CENTERS WILL ENROLL PATIENTS. “ The development of BT-001 is progressing well and we are pleased to start this clinical trial in France with patients being enrolled across the country in four reference clinical centers, and in other hospitals in Europe.

Trials 40
Trials Antibody Engineer Clinical Trials 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 32,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024